Analysts expect that Magellan Health Inc (NASDAQ:MGLN) will post $1.41 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Magellan Health’s earnings, with the lowest EPS estimate coming in at $1.38 and the highest estimate coming in at $1.45. Magellan Health posted earnings of $2.55 per share during the same quarter last year, which would indicate a negative year over year growth rate of 44.7%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Magellan Health will report full year earnings of $4.57 per share for the current year, with EPS estimates ranging from $4.56 to $4.60. For the next year, analysts anticipate that the company will post earnings of $4.50 per share, with EPS estimates ranging from $4.28 to $4.89. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Magellan Health.

Magellan Health (NASDAQ:MGLN) last posted its earnings results on Wednesday, November 7th. The company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.28. Magellan Health had a net margin of 1.49% and a return on equity of 10.93%. The business had revenue of $1.85 billion during the quarter, compared to the consensus estimate of $1.85 billion. During the same quarter in the previous year, the firm posted $1.64 EPS. The firm’s revenue was up 30.6% on a year-over-year basis.

Several research analysts have recently weighed in on the stock. TheStreet cut shares of Magellan Health from a “b-” rating to a “c+” rating in a research note on Friday, November 9th. ValuEngine cut shares of Magellan Health from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 28th. BidaskClub cut shares of Magellan Health from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 31st. Raymond James dropped their price target on shares of Magellan Health from $105.00 to $85.00 and set a “buy” rating on the stock in a research note on Monday, July 30th. Finally, Zacks Investment Research cut shares of Magellan Health from a “hold” rating to a “sell” rating in a research note on Saturday, October 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. Magellan Health has an average rating of “Hold” and a consensus price target of $88.75.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. purchased a new position in shares of Magellan Health during the 2nd quarter valued at $131,000. Jane Street Group LLC purchased a new position in shares of Magellan Health during the 3rd quarter valued at $220,000. Jefferies Group LLC purchased a new position in shares of Magellan Health during the 3rd quarter valued at $243,000. Commonwealth Bank of Australia purchased a new position in shares of Magellan Health during the 3rd quarter valued at $244,000. Finally, Verition Fund Management LLC purchased a new position in shares of Magellan Health during the 2nd quarter valued at $248,000. Institutional investors own 98.92% of the company’s stock.

Shares of Magellan Health stock opened at $54.40 on Thursday. The firm has a market cap of $1.36 billion, a PE ratio of 9.89, a price-to-earnings-growth ratio of 1.55 and a beta of 0.52. Magellan Health has a 1-year low of $54.18 and a 1-year high of $112.25. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.67 and a current ratio of 1.72.

About Magellan Health

Magellan Health, Inc provides healthcare management services in the United States. It operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine for health plans, care organizations, and employers.

Featured Story: Find a Trading Strategy That Works

Get a free copy of the Zacks research report on Magellan Health (MGLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Magellan Health (NASDAQ:MGLN)

Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.